Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8K5Z6)

Drug Name

Motexafin lutetium Drug Info

Synonyms

Lutetium texaphyrin; Lu-Tex; Motexafin lutetium < USAN; Optrin (Pharmacyclics); PCI-0123; Antrin (Pharmacyclics, US, US); Lutrin (National Cancer Institute (US), US; Pharmacyclics, , , JP); (PB-7-11-233'2'4)-Bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24

Indication

Disease Entry	ICD 11	Status	REF
Artery stenosis	BD52	Phase 3	[1]

Cross-matching ID

PubChem CID: 3081907
CAS Number: CAS 156436-90-7
TTD Drug ID: DM8K5Z6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Prostate specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PRX-302	DMEH641	Prostate cancer	2C82.0	Phase 3	[2]
Rilimogene galvacirepvec	DMGTCI0	Prostate cancer	2C82.0	Phase 3	[3]
ProstaVac	DM5FZH4	Prostate hyperplasia	GA90	Phase 3	[4]
ADXS-PSA	DMOPVET	Prostate cancer	2C82.0	Phase 1/2	[4]
MVA-BN Breast	DMFMW5C	Prostate cancer	2C82.0	Phase 1	[5]
PMID23692593C20	DM1T9LJ	Discovery agent	N.A.	Investigative	[6]
VTT-201	DMT967L	Prostate cancer	2C82.0	Investigative	[4]
ProstaRex	DM9GFOM	Prostate cancer	2C82.0	Investigative	[4]
Anti-PSA mabs	DMO21T7	Prostate cancer	2C82.0	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostate specific antigen (KLK3)	TTS78AZ	KLK3_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76.
2	Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54.
3	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
5	Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44.
6	Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. J Med Chem. 2013 Jun 13;56(11):4224-35.